Search

Your search keyword '"Coulie, Pierre G."' showing total 21 results
Start Over Author "Coulie, Pierre G." Publication Year Range Last 3 years
21 results on '"Coulie, Pierre G."'

3. Rôles du récepteur PD-1 et du facteur de transcription EOMES dans l’homéostasie des lymphocytes T CD8+ hépatiques

Author

Goriely, Stanislas, Corazza, Francis, Coulie, Pierre G, Dewals, Benjamin, Parmentier, Marc, Willems, Fabienne, Meylan, Etienne, Le Moine, Marie, Goriely, Stanislas, Corazza, Francis, Coulie, Pierre G, Dewals, Benjamin, Parmentier, Marc, Willems, Fabienne, Meylan, Etienne, and Le Moine, Marie

Abstract

Le récepteur co-inhibiteur PD-1 joue un rôle majeur dans l’homéostasie des lymphocytes T et la tolérance périphérique. Les souris déficientes pour le récepteur PD-1 développent des maladies auto-immunes. Par ailleurs, il est bien connu que les patients sous traitement par inhibiteur de points de contrôle anti-PD1 sont à risque de réactions immuno-médiées. Ces exemples soulignent l’importance du rôle du récepteur PD-1 dans la physiologie de l’immunité T. Même si le récepteur PD-1 a été étudié de façon exhaustive dans des situations pathologiques, telles le cancer, son rôle en conditions physiologiques est beaucoup moins connu. Le foie contribue à l’homéostasie du système immunitaire et il a été démontré que cet organe participait à l’élimination de clones de lymphocytes T activés. Avec nos recherches, nous confirmons que l’absence de voies PD-1 efficaces est associée à une expansion de lymphocytes T CD8+ hépatiques. De façon intéressante et originale, nous observons que cette expansion est oligoclonale et que ces clones expriment un profil de différenciation terminale avec des taux élevés des facteurs de transcription EOMES et TOX. A l’aide de techniques d’invalidation ou de surexpression de gènes, nous avons pu démontrer qu’EOMES est nécessaire à l’expansion clonale des lymphocytes T CD8+ en absence de PD-1. Des analyses du profil épigénétique montrent que ces clones ont des modifications épigénétiques spécifiques, différentes des autres populations lymphocytaires résidentes du foie. Pour terminer, nos analyses unicellulaires de séquençage de l’ARN associées à des analyses du répertoire du TCR suggèrent fortement que ces cellules se développent à partir de lymphocytes T résidents du foie. Grâce à ces résultats, nous avons mis en évidence un nouveau rôle des voies PD-1 dans l’homéostasie des lymphocytes T CD8+ du foie., Doctorat en Sciences médicales (Médecine), info:eu-repo/semantics/nonPublished

Published
2023

4. Supplementary Data from Frequency of Circulating Tregs with Demethylated FOXP3 Intron 1 in Melanoma Patients Receiving Tumor Vaccines and Potentially Treg-Depleting Agents

Author

de Vries, I. Jolanda M., primary, Castelli, Chiara, primary, Huygens, Caroline, primary, Jacobs, Joannes F.M., primary, Stockis, Julie, primary, Schuler-Thurner, Beatrice, primary, Adema, Gosse J., primary, Punt, Cornelis J.A., primary, Rivoltini, Licia, primary, Schuler, Gerold, primary, Coulie, Pierre G., primary, and Lucas, Sophie, primary

Published
2023
Full Text
View/download PDF

5. Supplementary Table 1 from Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients

Author

Tel, Jurjen, primary, Aarntzen, Erik H.J.G., primary, Baba, Tetsuro, primary, Schreibelt, Gerty, primary, Schulte, Barbara M., primary, Benitez-Ribas, Daniel, primary, Boerman, Otto C., primary, Croockewit, Sandra, primary, Oyen, Wim J.G., primary, van Rossum, Michelle, primary, Winkels, Gregor, primary, Coulie, Pierre G., primary, Punt, Cornelis J.A., primary, Figdor, Carl G., primary, and de Vries, I. Jolanda M., primary

Published
2023
Full Text
View/download PDF

7. Supplementary Figure 2 from Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients

Author

Tel, Jurjen, primary, Aarntzen, Erik H.J.G., primary, Baba, Tetsuro, primary, Schreibelt, Gerty, primary, Schulte, Barbara M., primary, Benitez-Ribas, Daniel, primary, Boerman, Otto C., primary, Croockewit, Sandra, primary, Oyen, Wim J.G., primary, van Rossum, Michelle, primary, Winkels, Gregor, primary, Coulie, Pierre G., primary, Punt, Cornelis J.A., primary, Figdor, Carl G., primary, and de Vries, I. Jolanda M., primary

Published
2023
Full Text
View/download PDF

10. Supplementary Figure 1 from Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients

Author

Tel, Jurjen, primary, Aarntzen, Erik H.J.G., primary, Baba, Tetsuro, primary, Schreibelt, Gerty, primary, Schulte, Barbara M., primary, Benitez-Ribas, Daniel, primary, Boerman, Otto C., primary, Croockewit, Sandra, primary, Oyen, Wim J.G., primary, van Rossum, Michelle, primary, Winkels, Gregor, primary, Coulie, Pierre G., primary, Punt, Cornelis J.A., primary, Figdor, Carl G., primary, and de Vries, I. Jolanda M., primary

Published
2023
Full Text
View/download PDF

11. Supplementary Table 2 from Natural Human Plasmacytoid Dendritic Cells Induce Antigen-Specific T-Cell Responses in Melanoma Patients

Author

Tel, Jurjen, primary, Aarntzen, Erik H.J.G., primary, Baba, Tetsuro, primary, Schreibelt, Gerty, primary, Schulte, Barbara M., primary, Benitez-Ribas, Daniel, primary, Boerman, Otto C., primary, Croockewit, Sandra, primary, Oyen, Wim J.G., primary, van Rossum, Michelle, primary, Winkels, Gregor, primary, Coulie, Pierre G., primary, Punt, Cornelis J.A., primary, Figdor, Carl G., primary, and de Vries, I. Jolanda M., primary

Published
2023
Full Text
View/download PDF

16. Abstract P4-07-16: B-IMMUNE final analysis: a phase Ib/II study of durvalumab combined with dose-dense EC in a neoadjuvant setting for patients with locally advanced luminal B HER2(-) or triple negative breast cancers

Author

Devaux, Alix, primary, Beniuga, Gabriela, additional, Quaghebeur, Claire, additional, Henry, Stéphanie, additional, Van Bockstal, Mieke, additional, Galant, Christine, additional, Delrée, Paul, additional, Canon, Jean-Luc, additional, Honhon, Brigitte, additional, Korman, Dominique, additional, Verschaeve, Vincent, additional, Lonchay, Christophe, additional, Lefevre, Sarah, additional, D’Hondt, Lionel, additional, Berlière, Martine, additional, Delmarcelle, Sophie, additional, Mine, Jean-Michel, additional, Willems, Timour, additional, Müller, Gebhard, additional, Myant, Nathalie, additional, Bar, Isabelle, additional, Haussy, Sandy, additional, Coulie, Pierre G., additional, Duhoux, François P., additional, and Carrasco, Javier, additional

Published
2023
Full Text
View/download PDF

19. Pandemic chilblains: Are they SARS-CoV-2-related or not?

Author

UCL - (SLuc) Service de dermatologie, UCL - SSS/DDUV/GECE - Génétique cellulaire, De Greef, Axel, Coulie, Pierre G., Baeck, Marie, UCL - (SLuc) Service de dermatologie, UCL - SSS/DDUV/GECE - Génétique cellulaire, De Greef, Axel, Coulie, Pierre G., and Baeck, Marie

Abstract

The exact etiopathology of chilblains observed during the Coronavirus Disease 2019 (COVID-19) pandemic is still unclear. Initially, SARS-CoV-2 appeared as the obvious causing agent, but two years of various investigations have failed to convincingly support its direct implication. Most affected individuals have no detectable virus, no anti-SARS-CoV-2 antibodies and no symptoms of COVID-19. Analyses of skin biopsies similarly failed to unambiguously demonstrate presence of the virus or its genome. In a recent hypothesis, SARS-CoV-2 would cause the lesions before being promptly eliminated by unusually strong type I interferon responses. With others, we feel that environmental factors have not been sufficiently considered, in particular cold exposure related to unprecedented containment measures. The cause of pandemic chilblains remains a stimulating puzzle which warrants further investigation.

Published
2022

20. Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis

Author

Lecomte, Sara, Devreux, Julien, de Streel, Grégoire, van Baren, Nicolas, Havelange, Violaine, Schröder, David, Vaherto, Noora, Vanhaver, Christophe, Vanderaa, Christophe, Dupuis, Noémie, Pecquet, Christian, Coulie, Pierre G., Constantinescu, Stefan N., and Lucas, Sophie

Abstract

Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by the clonal expansion of myeloid cells, notably megakaryocytes (MKs), and an aberrant cytokine production leading to bone marrow (BM) fibrosis and insufficiency. Current treatment options are limited. TGF-β1, a pro-fibrotic and immunosuppressive cytokine, is involved in PMF pathogenesis. While all cell types secrete inactive, latent TGF-β1, only a few activate the cytokine via cell type–specific mechanisms. The cellular source of the active TGF-β1 implicated in PMF is not known. Transmembrane protein GARP binds and activates latent TGF-β1 on the surface of regulatory T lymphocytes (Tregs) and MKs or platelets. Here, we found an increased expression of GARP in the BM and spleen of mice with PMF and tested the therapeutic potential of a monoclonal antibody (mAb) that blocks TGF-β1 activation by GARP-expressing cells. GARP:TGF-β1 blockade reduced not only fibrosis but also the clonal expansion of transformed cells. Using mice carrying a genetic deletion of Garpin either Tregs or MKs, we found that the therapeutic effects of GARP:TGF-β1 blockade in PMF imply targeting GARP on Tregs. These therapeutic effects, accompanied by increased IFN-γ signals in the spleen, were lost upon CD8 T-cell depletion. Our results suggest that the selective blockade of TGF-β1 activation by GARP-expressing Tregs increases a CD8 T-cell-mediated immune reaction that limits transformed cell expansion, providing a novel approach that could be tested to treat patients with myeloproliferative neoplasms.

Published
2022
Full Text
View/download PDF

21. Facts and Hopes in Cancer Antigens Recognized by T Cells.

Author

Brochier W, Bricard O, and Coulie PG

Subjects
Humans, Antigens, Neoplasm, Immunotherapy, T-Lymphocytes, Neoplasms genetics
Abstract

T cells are key effectors of our immune response against tumors and exert their antitumor effects upon recognizing a variety of tumor-specific peptides presented by HLA molecules on the surface of tumor cells. The identification of the tumor-specific antigens of a given tumor is not required for immune checkpoint therapy (ICT), which mainly reactivates existing tumor-specific T cells together with T cells of unknown specificities. To decrease the activation of non-tumor-specific T cells, active or passive immunizations against tumor-specific antigens are considered. These immunizations require the identification of at least some of the tumor-specific antigens displayed on the tumor cells of a patient. While this has become an easy task for tumors with a large number of mutations generating neoantigens, it remains difficult for the remainder. Here, we review some facts about human tumor-specific or tumor-associated antigens, as well as some hopes for their future use in cancer immunotherapy., (©2022 American Association for Cancer Research.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results